Experienced in Chronic Graft Versus Host Disease (cGvHD)

Dr. Michael W. Boyer

Pediatric Hematology Oncology
100 N Medical Dr, Bmt, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Chronic Graft Versus Host Disease (cGvHD)
100 N Medical Dr, Bmt, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Boyer is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Boyer is rated as an Experienced provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Hepatic Venoocclusive Disease with Immunodeficiency, Childhood Acute Myeloid Leukemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Chronic Graft Versus Host Disease (cGvHD).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in UT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

100 N Medical Dr, Bmt, Salt Lake City, UT 84113

Additional Areas of Focus

Dr. Boyer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 2
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2023
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Biological
Study Phase: Phase 2
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies
Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: August 11, 2020
Intervention Type: Biological, Procedure
Study Phase: Phase 1
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Enrollment Status: Completed
Publish Date: August 10, 2020
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 11 Less Clinical Trials

20 Total Publications

Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
Journal: Leukemia
Published: November 11, 2021
Similar Doctors
Advanced in Chronic Graft Versus Host Disease (cGvHD)
Dr. Ahmad Rayes
Pediatric Hematology Oncology
Advanced in Chronic Graft Versus Host Disease (cGvHD)
Dr. Ahmad Rayes
Pediatric Hematology Oncology
100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.2 miles away)
801-662-4700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ahmad Rayes is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Rayes is rated as an Experienced provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Severe Combined Immunodeficiency (SCID), Chronic Graft Versus Host Disease (cGvHD), Chronic Granulomatous Disease, Infantile Neutropenia, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boyer's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile